VPI-2690B
Product Specifications
Target
Integrin, TGF-beta/Smad
Related Pathways
Stem Cells, Cytoskeletal Signaling
Bioactivity
VPI-2690B is a human-derived monoclonal antibody (mAb) that targets Integrin αVβ3. It is capable of modulating TGF-β signaling and can be utilized in research related to diabetic nephropathy.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6091484-01 5 mg
1,3,4,6-Tetra-O-acetyl-2- (2',3',4'-tri-O-benzoyl-a-L-fucopyranosyl) -galactopyranose_x000B_
Sign In for Pricing
View Details MBS6091484-02 5x 5 mg
1,3,4,6-Tetra-O-acetyl-2- (2',3',4'-tri-O-benzoyl-a-L-fucopyranosyl) -galactopyranose_x000B_
Sign In for Pricing
View Details 
sc-423648-LAC-2 200 µL
Vmn2r104 Lentiviral Activation Particles (m2)
Sign In for Pricing
View Details